Shots:

• The acquisition expands the anti-infectives pipeline with the addition of Amplyx’s P-II candidate- Fosmanogepix (APX001) which is being evaluated in both IV and oral formulations for the treatment of patients with invasive fungal infections
• Pfizer also retains ownership of the Amplyx early-stage pipeline- including antiviral (MAU868) and antifungal (APX2039) therapies. The acquisition follows an initial equity investment by Pfizer in December 2019 as part of Amplyx’s Series C funding
• Fosmanogepix has demonstrated broad-spectrum activity in-vitro and showed wide distribution to various tissues- including brain- lung- kidney- and eye

  Ref: Pfizer | Image: PRNewswire